Company: RPTX
Filing Date: 2025-11-20
Form Type: DEFA14A
Source: 0001193125-25-290058
Chunk: 3

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-20
Form: DEFA14A
Chunk 3
---
the “Proxy Statement”) and which will be available on the Company’s EDGAR and SEDAR+ profiles. While the list of factors presented here is, and
the list of factors to be presented in the Proxy Statement will be, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties related to the Transaction.

Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this news
release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange
Commission (the “SEC”) and the Autorité des Marchés Financiers (Quebec) (“AMF”) on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at
.